Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x.
Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553-52574. doi:10.18632/oncotarget.9651.
Mai J, Wu L, Yang L, et al. Therapeutic strategies targeting folate receptor α for ovarian cancer. Front Immunol. 2023;14:1254532. doi:10.3389/fimmu.2023.1254532.
Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425-429. doi:10.1634/theoncologist.2018-0459.
Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020;17(6):349-359. doi:10.1038/s41571-020-0339-5.
Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619-626.doi:10.1016/j.ygyno.2007.11.020.
Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6:360-369. doi:10.1017/j.molonc.2011.11.010.
